Aclaris Therapeutics to stop development of rheumatoid arthritis drug
Nov 13 (Reuters) - Aclaris Therapeutics ACRS.O on Monday said it will stop development of its rheumatoid arthritis treatment after it failed in a mid-stage trial. (Reporting by Sriparna Roy in Bengaluru; Editing by Maju Samuel) ((Sriparna.Roy@thomsonreuters.com;))
Recent news on Aclaris Therapeutics
See all newsAclaris Therapeutics Q1 net loss widens on higher R&D spending
Brief: Aclaris Therapeutics Q1 EPS USD -0.15 Vs. IBES Estimate USD -0.16
Brief: Aclaris Therapeutics Says Positive Full Top Line Results From Phase 1A Clinical Trial Of ATI-055
Brief: Aclaris Therapeutics Completes Enrollment In Phase 2 Trial Of Bosakitug (Ati-045) In Atopic Dermatitis
Aclaris Q4 loss narrows, but misses analysts' expectations